<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330937</url>
  </required_header>
  <id_info>
    <org_study_id>UCAMCFE-0008</org_study_id>
    <nct_id>NCT04330937</nct_id>
  </id_info>
  <brief_title>Clinical Trial on the Effectiveness of Citrolive</brief_title>
  <acronym>CITROXI</acronym>
  <official_title>Clinical Trial on the Effectiveness of Citrolive® to Decrease Oxidation of Low Density Lipoproteins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Católica San Antonio de Murcia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial consists in checking the antioxidant effect of citrolive on low density
      cholesterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial consists in checking the antioxidant effect of citrolive on low density
      cholesterol. To do this, volunteers consume the product under study or placebo for three
      months.

      Tests will be performed before and after ingestion of the product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>The change in systolic and diastolic blood pressure is observed after three months of intake of the product under investigation</time_frame>
    <description>The systolic and diastolic blood pressure was measured with an OMRON oscilimétrilo sphygmomanometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry and blood count</measure>
    <time_frame>The change is observed after three months of intake of the product under investigation</time_frame>
    <description>the hematological profile is analyzed with the Horiba ABX Oentra 80 analyzer. Biochemical profile with the ILAB 600 analyzer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>The change is observed after three months of intake of the product under investigation</time_frame>
    <description>Measured in Kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>The change is observed after three months of intake of the product under investigation</time_frame>
    <description>Measured in cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>The change is observed after three months of intake of the product under investigation</time_frame>
    <description>Weight and height are combined for BMI report in kg / m ^ 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perimeters</measure>
    <time_frame>The change is observed after three months of intake of the product under investigation</time_frame>
    <description>Measured in cm. Waist, hip, waist / hip index, relaxed biceps, contracted biceps, medial thigh, twin or calf.
Folds (mm) (tricipítal, subscapular, suprailiac anterior or supraspinal, abdominal, quadricipital or thigh, leg or calf medial, bicipital, iliocrestal).
Diameters (cm) (radiocubital or wrist biestiloid, humeral or elbow bicpicondiolo, femoral or knee bicondiol).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Folds</measure>
    <time_frame>The change is observed after three months of intake of the product under investigation</time_frame>
    <description>Measured in mm. Tricipítal, subscapular, suprailiac anterior or supraspinal, abdominal, quadricipital or thigh, leg or calf medial, bicipital, iliocrestal.
Diameters (cm) (radiocubital or wrist biestiloid, humeral or elbow bicpicondiolo, femoral or knee bicondiol).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameters</measure>
    <time_frame>The change is observed after three months of intake of the product under investigation</time_frame>
    <description>Measured in cm. Radiocubital or wrist biestiloid, humeral or elbow bicpicondiolo, femoral or knee bicondiol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional record</measure>
    <time_frame>Measurements are made at the beginning and after 90 days of product consumption.</time_frame>
    <description>Volunteers record dietary intake for three days in a notebook. They will describe the amount of food they consume in grams in order to assess changes in intake during the clinical trial.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cardiovascular Risk</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volunteers consume 1 capsule per day for 3 months. (500 mg citrolive).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group Placebo (sucrose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>volunteers consume 1 capsule per day for 3 months. (saccharose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietetics</intervention_name>
    <description>90 days of consumption</description>
    <arm_group_label>control group Placebo (sucrose)</arm_group_label>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Not belonging to the group of individuals considered as priorities by the Third Joint
             Task Force for the prevention of cardiovascular diseases due to high risk.

          2. Present total cholesterol figures greater than 200 milligrams / deciliter and / or low
             density cholesterol figures greater than 130 milligrams / deciliter so that after
             applying the cardiovascular risk table (SCORE) they present a current risk of less
             than 5% of suffer an ischemic event in a period of 10 years, being without
             pharmacological treatment.

          3. Present several cardiovascular risk factors with cholesterolemia figures close to 200
             milligrams / deciliters and / or low density cholesterol figures close to 130
             milligrams / deciliters.

        Exclusion Criteria:

        1. chronic or terminal illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica San Antonio de Murcia</investigator_affiliation>
    <investigator_full_name>Francisco Javier López Román</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

